Clinical trial
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
NCT00239408 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00239408 |
|---|---|
| Title | Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal). |
| Official title | Spiriva Assessment of FEV1 - (SAFE-Portugal). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Treatment in Patients With COPD. A Three-month Parallel Group, Double-blind, Randomised, Placebo-controlled Study. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Device, Drug |
| Interventions | Pulmonary function Testing, tiotropium bromide |
| Enrollment | 311 |
| Start date | Dec 1, 2002 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Oct 17, 2005 |
| Last update posted | Nov 1, 2013 |
| Countries | Portugal |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: